Catalog No.: PC-21211Not For Human Use, Lab Use Only.
GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively, GSK-J4 s a cell permeable prodrug of GSK-J1.
GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively, GSK-J4 s a cell permeable prodrug of GSK-J1. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with IC50 of 9 uM. GSK-J4 prevents the JMJD3-induced loss of nuclear H3K27me3 immunostaining in Flag-JMJD3-transfected HeLa cells. GSK-J4 inhibits JMJD3 expression that is induced by TGF-β1, inhibits H3K4 demethylation at Xist, Nodal, and HoxC13 in female embryonic stem cells. GSK-J4 attenuates the development of kidney disease in diabetic mice.
